Healthcare Professionals​

This is an international website for NERLYNX® dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am Healthcare Professional inside the EU and I have read the information above​, the Legal Notice and the Privacy Policy

Non Healthcare Professionals

This is an international website for NERLYNX® dedicated to Healthcare Professionals.

I am not a Healthcare Professional inside the EU.


Pierre Fabre is responsible for NERLYNX® commercialisation in many countries

Pierre Fabre has always favored a partnership-based approach to research, convinced that complementarity and the sharing of expertise are accelerators of innovation. Puma Biotechnology and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialise NERLYNX® within many countries. Over the years, this agreement has evolved, accessing a true innovation for patients in more and more territories.

Territories indicated in blue are those where Pierre Fabre owns the license of NERLYNX®:

world map

Europe: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Switzerland, Albania, Bosnia-Herzegovina, Croatia, Kosovo, Republic of Macedonia, Montenegro, Serbia

Africa: Tunisia, Algeria, Morocco, Burundi, Republic of the Congo, Benin, Burkina Faso, Cameroon, Chad, Ivory Coast, Gabon, Guinea, Libya, Madagascar, Mali, Mauritania, Mauritius, Niger, Senegal, Togo, Djibouti, Central African Republic, Egypt, South Africa, Sudan

Asia: Iran, Iraq, Saudi Arabia, Yemen, Syria, Jordan, United Arab Emirates, Lebanon, Oman, Kuwait, Qatar, Bahrain, Turkey, China, Hong Kong, Taiwan, Macau

NERLYNX® may not be approved and reimbursed in all these countries. Please refer to local prescribing information.

Contenu de la pop in (ici, un H3)

A noter que le contenu de la pop in est prise en compte pour le SEO.

Il est donc nécessaire de bien baliser les titres. Nous conseillons d'utiliser un H2 ou un H3 (pas de H1).